Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Anji Pharma Pays $2 Million Upfront for China Rights to Novartis Candidate

publication date: Dec 20, 2018

Anji Pharma, a Boston-Shanghai startup, in-licensed China rights to pradigastat, a potential treatment for hyperlipoproteinemia currently in a Phase III trial, from Novartis. Hyperlipoproteinemia results from an inability to break down lipids or fats, specifically cholesterol and triglycerides. Anji paid Novartis $2 million upfront and will make additional milestone and royalty payments. Initially, Anji will conduct China trials for the candidate; it plans to eventually pursue additional indications. Anji is a genomically based drug discovery company with Shanghai clinical operations. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital